肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看,按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和(导航里的「临床试验」板块只收在招的那部分,不另计入)。
Early Recurrence of HCC Is Driven by Inflammation-Related HIF-1α Independent Angiogenesis Rather than Hypoxia-Induced Immune Escape.
早期 HCC 复发表现为不依赖 HIF-1 的血管生成,并伴有空间免疫耗竭,支持采用整合免疫分析而非单一血管生成标志物。
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellu
Tumor-infiltrating CD8(+) T-cell numbers and serum C-reactive protein levels as a prognostic biomarker in hepatocellular carcinoma patients receiving
这些发现提示,CD8⁺ TIL 数量与血清 CRP 水平的组合可能作为预测阿替利珠单抗联合贝伐珠单抗在 HCC 患者中疗效的有用生物标志物。
Combined Immune Therapy Proves Effective in an Advanced Hepatocellular Carcinoma Patient With Poor Liver Reserve: A Case Report.
Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical se
SCG101 T 细胞疗法在临床前模型以及一例原发性 HBV-HCC 合并慢性乙型肝炎患者中显示出令人鼓舞的疗效和安全性,具有清除 HBsAg+细胞并在单次给药后实现持续肿瘤控制的能力。
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.
Therapeutic efficacy of dendritic cell injection in advanced hepatocellular carcinoma: the role of natural killer and T lymphocytes.
DC 注射可能是晚期 HCC 患者的有效治疗方法,可提高生活质量。
MEMBER ACCOUNT
登录成功会直接打开下一页。